[1]刘艳佳,李 娜,王业涤,等.血浆游离DNA甲基化靶向测序在乳腺癌中的应用价值[J].医学信息,2023,36(04):88-93.[doi:10.3969/j.issn.1006-1959.2023.04.017]
　LIU Yan-jia,LI Na,WANG Ye-di,et al.Application Value of Plasma Free DNA Methylation Targeted Sequencing in Breast Cancer[J].Journal of Medical Information,2023,36(04):88-93.[doi:10.3969/j.issn.1006-1959.2023.04.017]
点击复制

血浆游离DNA甲基化靶向测序在乳腺癌中的应用价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年04期
页码:
88-93
栏目:
论著
出版日期:
2023-02-15

文章信息/Info

Title:
Application Value of Plasma Free DNA Methylation Targeted Sequencing in Breast Cancer
文章编号:
1006-1959（2023）04-0088-06
作者:
刘艳佳; 李 娜; 王业涤; 等
（1.佳木斯大学临床医学院，黑龙江 佳木斯 154000；2.佳木斯大学附属第一医院肿瘤外科，黑龙江 佳木斯 154003）
Author(s):
LIU Yan-jia; LI Na; WANG Ye-di; et al.
(1.School of Clinical Medicine,Jiamusi UniversitymJiamusi 154000,Heilongjiang,China;2.Department of Oncology Surgery,the First Affiliated Hospital of Jiamusi University,Jiamusi 154003,Heilongjiang,China)
关键词:
乳腺癌; DNA甲基化; CCDC181; 血浆游离DNA
Keywords:
Breast cancer; DNA methylation; CCDC181; Plasma free DNA
分类号:
R736.3
DOI:
10.3969/j.issn.1006-1959.2023.04.017
文献标志码:
A
摘要:
目的 检测乳腺癌（BRC）患者血浆游离DNA（Cf-DNA）的甲基化水平，并分析其临床应用价值。方法 收集2021年12月-2022年6月就诊于佳木斯大学附属第一医院肿瘤外科50例患者血液标本，其中乳腺癌患者（Ⅰ~Ⅲ期）30例为实验组（tumor组），乳腺良性疾病患者20例为对照组（control组），采用化学发光法检测血清糖类抗原153（CA153）、血清糖类抗原125（CA125）、癌胚抗原（CEA）水平，提取实验组及对照组患者Cf-DNA，行高通量甲基化靶向测序检测，评估甲基化水平；ROC曲线评估Cf-DNA和CA153、CA125、CEA单独及联合检测筛查乳腺癌的临床价值。结果 实验组CA153、CA125、CEA水平均高于对照组，差异有统计学意义（P＜0.05）；两组血浆Cf-DNA浓度比较，差异无统计学意义（P＞0.05）；两组CCDC181启动子区甲基化水平、总体甲基化水平比较，差异均有统计学意义（P＜0.05）；ROC曲线显示，血清CEA诊断乳腺癌的曲线下面积（AUC）=0.766（95%CI：0.633~0.897），CA153的AUC=0.730（95%CI：0.591~0.869），CA125的AUC=0.788（95%CI：0.661~0.914），三者联合的AUC=0.923（95%CI：0.852~0.993），联合诊断的灵敏度、特异度、AUC均高于CA153、CA125和CEA单一诊断；CpG2120诊断乳腺癌的灵敏度及特异度最高，CpG1984、CpG2016及CpG2120联合诊断及单一诊断的灵敏度、特异度、AUC高于CA153、CA125和CEA单一或联合诊断。结论 血浆Cf-DNA甲基化检测在乳腺癌筛查中的敏感性和特异性较高，具有较好的临床应用价值，联合肿瘤标志物可以提高乳腺癌的早期诊断率。
Abstract:
Objective To detect the methylation level of plasma free DNA (cell-free DNA, Cf-DNA) in patients with breast cancer (BRC) and analyze its clinical value.Methods The blood samples of 50 patients who were admitted to the Department of Oncology Surgery, the First Affiliated Hospital of Jiamusi University from December 2021 to June 2022 were collected, including 30 patients with breast cancer (stage Ⅰ-Ⅲ) as the experimental group (tumor group) and 20 patients with benign breast disease as the control group ( control group ). The levels of serum carbohydrate antigen 153 (CA153), serum carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA) were detected by chemiluminescence. Cf-DNA was extracted from the experimental group and the control group, and high-throughput methylation targeted sequencing was performed to evaluate the methylation level. ROC curve was used to evaluate the clinical value of Cf-DNA and CA153, CA125, CEA alone and combined detection in screening breast cancer.Results The levels of CA153, CA125 and CEA in the experimental group were higher than those in the control group, the difference was statistically significant (P<0.05). There was no significant difference in plasma Cf-DNA concentration between the two groups (P>0.05). There were significant differences in the methylation level of CCDC181 promoter region and the overall methylation level between the two groups (P<0.05). The ROC curve showed that the area under the curve (AUC) of serum CEA in the diagnosis of breast cancer was 0.766 (95%CI:0.633-0.897), the AUC of CA153 was 0.730 (95%CI:0.591-0.869), the AUC of CA125 was 0.788 (95%CI:0.661-0.914), and the combined AUC was 0.923 (95%CI:0.852-0.993), while the sensitivity, specificity and AUC of combined diagnosis were higher than those of CA153, CA125 and CEA alone; the sensitivity and specificity of CpG2120 in the diagnosis of breast cancer were the highest; the sensitivity, specificity and AUC of CpG1984, CpG2016 and CpG2120 combined diagnosis and single diagnosis were higher than those of CA153, CA125 and CEA single or combined diagnosis.Conclusion Plasma Cf-DNA methylation detection has high sensitivity and specificity in breast cancer screening, and has good clinical application value. Combined with tumor markers, it can improve the early diagnosis rate of breast cancer.

参考文献/References:

[1]Fernandes Marques J,Pereira Reis J,Fernandes G,et al.Circulating Tumor DNA: A Step into the Future of Cancer Management[J].Acta Cytol,2019,63(6):456-465.[2]Pan X,Ji P,Deng X,et al.Genome-wide analysis of methylation CpG sites in gene promoters identified four pairs of CpGs-mRNAs associated with lung adenocarcinoma prognosis[J].Gene,2021,810:146054.[3]Wang SC,Liao LM,Ansar M,et al.Automatic Detection of the Circulating Cell-Free Methylated DNA Pattern of GCM2, ITPRIPL1 and CCDC181 for Detection of Early Breast Cancer and Surgical Treatment Response[J].Cancers,2021,13(6):1375.[4]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2021版)[J].中国癌症杂志,2021,31(10):954-1040.[5]唐林,陈巍魏,管晓翔.AJCC第8版乳腺癌分期系统更新的解读[J].临床肿瘤学杂志,2017,22(11):1038-1040.[6]Barba D,Leon-Sosa A,Lugo P,et al.Breast cancer, screening and diagnostic tools: All you need to know[J].Critical Reviews in Oncology/Hematology,2021,157:103174.[7]Zhuang Z,Yang Z,Raj ANJ,et al.Breast ultrasound tumor image classification using image decomposition and fusion based on adaptive multi-model spatial feature fusion[J].Comput Methods Programs Biomed,2021,208:106221.[8]Bevers TB,Helvie M,Bonaccio E,et al.Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2018,16(11):1362-1389.[9]Schwartzberg LS,Kiedrowski LA.Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation[J].Therapeutic Advances in Medical Oncology,2021,13:17588359211006962.[10]Barault L,Amatu A,Siravegna G,et al.Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer[J].Gut,2018,67(11):1995-2005.[11]Palmieri M,Baldassarri M,Fava F,et al.Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients[J].Cancer Medicine,2020,9(6):2052-2061.[12]Zhang X,Zhao D,Yin Y,et al.Circulating cell-free DNA-based methylation patters for breast cancer diagnosis[J].NPJ Breast Cancer,2021,7(1):106.[13]Qiao G,Zhuang W,Dong B,et al.Discovery and validation of methylation signatures in circulating cell-free DNA for early detection of esophageal cancer: a case-control study[J].BMC Med,2021,19(1):243.[14]Fernandez-Garcia D,Hills A,Page K,et al.Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer[J].Breast Cancer Research,2019,21(1):149.[15]Moss J,Zick A,Grinshpun A,et al.Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer[J].Annals of Oncology,2020,31(3):395-403.[16]Liu L,Toung JM,Jassowicz AF,et al.Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification[J].Annals of Oncology,2018,29(6):1445-1453.[17]Jain M,Ingole SD,Deshmukh RS,et al.CEA,CA153,and miRNA expression as potential biomarkers in canine mammary tumors[J].Chromosome Res,2021,29(2):175-188.[18]Schwarz T,Prieler B,Schmid JA,et al.Ccdc181 is a microtubule-binding protein that interacts with Hook1 in haploid male germ cells and localizes to the sperm tail and motile cilia[J].European Journal of Cell Biology,2017,96(3):276-288.[19]Gao C,Zhuang J,Li H,et al.Exploration of methylation-driven genes for monitoring and prognosis of patients with lung adenocarcinoma[J].Cancer Cell Int,2018,18:194.[20]Ren S,Gaykalova D,Wang J,et al.Discovery and development of differentially methylated regions in human papillomavirus-related oropharyngeal squamous cell carcinoma[J].International Journal of Cancer,2018,143(10):2425-2436.[21]Li R,Yang YE,Yin YH,et al.Methylation and transcriptome analysis reveal lung adenocarcinoma-specific diagnostic biomarkers[J].Journal of Translational Medicine,2019,17(1):324.[22]Ishihara H,Yamashita S,Fujii S,et al.DNA methylation marker to estimate the breast cancer cell fraction in DNA samples[J].Medical Oncology,2018,35(11):147.

相似文献/References:

[1]董 云.SPECT/CT 双时相99mTc- MIBI断层显像 在乳腺癌诊断中的应用[J].医学信息,2018,31(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
　DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Journal of Medical Information,2018,31(04):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]张益勋,胡逸萍,钟穗航,等.DNA甲基化在病理性瘢痕中的作用研究[J].医学信息,2018,31(09):46.[doi:10.3969/j.issn.1006-1959.2018.09.015]
　ZHANG Yi-xun,HU Yi-ping,ZHONG Sui-hang,et al.Study on the Role of DNA Methylation in Pathological Scars[J].Journal of Medical Information,2018,31(04):46.[doi:10.3969/j.issn.1006-1959.2018.09.015]
[3]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,31(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[4]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,31(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
　YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Journal of Medical Information,2018,31(04):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[5]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与 健康知识水平的影响[J].医学信息,2018,31(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
　LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Journal of Medical Information,2018,31(04):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[6]韩佳睿,张 苹,张 媛.迟发性运动障碍与DNA甲基化之间关系的研究进展[J].医学信息,2018,31(20):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
　HAN Jia-rui,ZHANG Ping,ZHANG Yuan.Advances in Research on the Relationship between Tardive Dyskinesia and DNA Methylation[J].Journal of Medical Information,2018,31(04):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
[7]张艳萍,曹 玉,孙国平.服用阿司匹林对乳腺癌患者生存获益的Meta分析[J].医学信息,2018,31(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
　ZHANG Yan-ping,CAO Yu,SUN Guo-ping.Meta Analysis of the Survival Benefit of Patients with Breast Cancer Treated with Aspirin[J].Journal of Medical Information,2018,31(04):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
[8]钟 磊,谢海燕,林 霖.电化学发光免疫分析技术检测肿瘤标志物在乳腺癌诊断中的应用[J].医学信息,2018,31(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
　ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Journal of Medical Information,2018,31(04):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[9]胡平华,黄 勤,李志华.含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比[J].医学信息,2018,31(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
　HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Journal of Medical Information,2018,31(04):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[10]阙海涛,曹 斌,秦志刚.EGFL7在乳腺癌中的研究进展[J].医学信息,2018,31(23):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
　QUE Hai-tao,CAO Bin,QIN Zhi-gang.Research Progress of EGFL7 in Breast Cancer[J].Journal of Medical Information,2018,31(04):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]

更新日期/Last Update: 1900-01-01